Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
24 stopped studies mapped to Bladder Urothelial Carcinoma and descendants · 79% state a reason
Over the 24 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With… | Phase 2 | withdrawn | Feb 17, 2026 | Memorial Sloan Kettering Cancer Center | The sponsor is no longer supporting the trial because they are no longer interested in studying the… | Other (stated, no rule matched) |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for…(ARTIA-Bladder) | N/A | terminated | Jan 26, 2023 | Varian, a Siemens Healthineers Company | Low enrollment | Enrollment / accrual |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With… | Phase 2 | withdrawn | Oct 3, 2022 | National Cancer Institute (NCI) | Feasibility issues | Other (stated, no rule matched) |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for…(GETUGV04) | N/A | terminated | Dec 20, 2011 | Institut du Cancer de Montpellier - Val d'Aurelle | not stated | Not stated |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant… | Phase 2 | terminated | Apr 11, 2019 | Stanford University | Difficulty with enrollment | Enrollment / accrual |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving… | — | terminated | Sep 22, 2021 | xCures | Sponsor request to terminate study due to enrollment numbers | Enrollment / accrual |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | Phase 1 | withdrawn | Jul 22, 2021 | Guru P. Sonpavde | Low Accrual | Enrollment / accrual |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial… | Phase 2 | terminated | Sep 15, 2016 | H. Lee Moffitt Cancer Center and Research Institute | Study closed early due to futility | Efficacy / futility |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma…(RESECT) | Early Phase 1 | terminated | Aug 30, 2017 | University Health Network, Toronto | Difficulties with accrual | Enrollment / accrual |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or… | Phase 1 | terminated | May 11, 2016 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of… | — | terminated | Jul 10, 2015 | University of Southern California | The PI left institution | Investigator |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | N/A | terminated | Mar 4, 2016 | University of Southern California | PI decided to revamp the protocol completely and will submit as new study. | Other (stated, no rule matched) |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial… | Phase 2 | withdrawn | Feb 1, 2018 | University of California, San Francisco | Study withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | — | withdrawn | Aug 3, 2015 | University of Southern California | No funding | Funding |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for… | N/A | withdrawn | Aug 3, 2017 | University of Southern California | No funding | Funding |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With… | N/A | withdrawn | Oct 25, 2016 | Mayo Clinic | not stated | Not stated |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy… | Phase 2 | withdrawn | Mar 24, 2016 | Mayo Clinic | not stated | Not stated |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 3, 2026source: clinicaltrials